相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination
Kyosuke Nakamura et al.
MOLECULAR CELL (2021)
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb et al.
EUROPEAN UROLOGY (2021)
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
Sara A. Hurvitz et al.
ONCOLOGIST (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
Matthew Raymond Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Therapeutic targeting of the DNA damage response in prostate cancer
Catherine H. Marshall et al.
CURRENT OPINION IN ONCOLOGY (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
R. Lozano Mejorada et al.
ANNALS OF ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pan-cancer landscape of homologous recombination deficiency
Luan Nguyen et al.
NATURE COMMUNICATIONS (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Isaac E. Kim et al.
BMC UROLOGY (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley et al.
NATURE (2019)
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2019)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
分享论文
